ProCE Banner Activity

CME

JAK Inhibitors in RA: Applying Evidence-Based Strategies in Clinical Decision-making

Video

Experts discuss the evidence-based application of recent efficacy and safety data for JAK inhibitors in RA to equip healthcare professionals in helping patients attain low disease activity/remission and improved quality of life.

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: January 10, 2023

Expiration: February 29, 2024

No longer available for credit.

Share

Faculty

Stanley B. Cohen

Stanley B. Cohen, MD

Clinical Professor
Department of Internal Medicine
University of Texas Southwestern Medical School
Co-Director
Division of Rheumatology
Presbyterian Hospital
Dallas, Texas

Janet Pope

Janet Pope

Professor of Medicine
Division of Rheumatology
Division of Epidemiology and Biostatistics
University of Western Ontario Schulich School of Medicine
Division Head
Rheumatology
St. Joseph’s Health Centre
London, Ontario, Canada

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

This activity is supported by an educational grant from

Lilly

Target Audience

US- and OUS-based rheumatologists and allied health professionals, excluding healthcare professionals located in the United Kingdom

Learning Objectives

  • Review recent efficacy and safety data for JAK inhibitor therapy in RA
  • Assess the benefits and risks of JAK inhibitor therapy for patients with RA based on patient comorbidities and risk factors
  • Incorporate practical management and risk mitigation strategies into comprehensive care plans for patients with RA receiving JAK inhibitor therapy

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Faculty Disclosure

Primary Author

Stanley B. Cohen, MD

Clinical Professor
Department of Internal Medicine
University of Texas Southwestern Medical School
Co-Director
Division of Rheumatology
Presbyterian Hospital
Dallas, Texas

Stanley B. Cohen, MD: researcher: AbbVie, Bristol-Myers Squibb, Gilead, Lilly, Pfizer.

Janet Pope,

Professor of Medicine
Division of Rheumatology
Division of Epidemiology and Biostatistics
University of Western Ontario Schulich School of Medicine
Division Head
Rheumatology
St. Joseph’s Health Centre
London, Ontario, Canada

Janet Pope, MD, MPH, FRCPC: consultant/advisor/speaker: AbbVie, Amgen, Astra Zeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Celltrion, EMERALD, Fresenius Kabi, GlaxoSmithKline, Janssen, Lilly, Mallinckrodt, Mitsubishi Tanabe Pharma, Novartis, Organon, Pfizer, Sandoz, Samsung, UCB, Viatris.

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose, except Vivian P. Bykerk, MD, FRCPC, and Vibeke Strand, MD, MACR, FACP as noted below:

Vivian P. Bykerk, MD, FRCPC: consultant/advisor/speaker: Bristol-Myers Squibb, Genzyme, Gilead Sciences, Janssen Global Services.

Vibeke Strand, MD, MACR, FACP: consultant/advisor: AbbVie, Amgen, Aria, AstraZeneca, Bayer, Bioventus, Blackrock, BMS, Boehringer Ingelheim, Celltrion, ChemoCentryx, EMD Serono, Endo, Equillium, Genentech/Roche, Gilead Sciences, Glenmark, GSK, Horizon, Inmedix, Janssen, Kiniksa, Kypha, Lilly, Merck, MiMedx, Novartis, Pfizer, Priovant, R-Pharm, Regeneron, Rheos, Samsung, Sandoz, Sanofi, Scipher, Setpoint, Sofusa, Spherix, Tonix.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
Credit Designation

CCO designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Additional Information

Participation in this self-study activity should be completed in approximately 1 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from January 10, 2023, through February 29, 2024:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.

 

Goal


The goal of this educational program is to improve knowledge and competence among learners regarding the appropriate use of JAK inhibitors in rheumatoid arthritis to help patients attain low disease activity/remission and improved quality of life.